UPDATE: Jefferies Raises PT on Allergan on Q4 EPS

In a report published Wednesday, Jefferies reiterated its Hold rating on Allergan AGN, and raised its price target from $95.00 to $100.00. Jefferies noted, “AGN did what it does best: beat EPS and gave strong guidance. Q4 adj-EPS of $1.15 ‘missed', but adjusting for the expected R&D tax credit that got delayed until Jan., EPS would have been $1.21 vs. JEF/Street $1.19/$1.18. 2013 EPS guidance was 0-2% above consensus. AGN is best-in-class, and deserves the premium multiple, but we see aspirational 10% LT REV growth as challenging with the pipeline is mostly early. Raise to $100.” Allergan closed on Tuesday at $106.70.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: Analyst ColorPrice TargetAnalyst RatingsJefferies
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!